Sanofi is reportedly weighing a bid for Insmed, sending Insmed shares up more than 21% on a takeover-interest report cited by Bloomberg News. The story, which said talks were ongoing and that a deal might take weeks to emerge, positioned Insmed as a potential blockbuster target given its respiratory franchise and growing revenue outlook. Insmed markets brensocatib (Brinsupri) and amikacin liposome inhalation suspension (Arikayce), and the report pointed to strong third-quarter results and rising sales projections as key drivers behind investor expectations. Insmed and Sanofi declined to comment, leaving the status of any negotiations uncertain. For Sanofi, an acquisition would add established respiratory assets and pipeline depth that could complement its broader respiratory strategy, including Dupixent co-marketing activities. For the sector, the headline underscores how marketed respiratory drugs remain attractive acquisition targets when cash-flow durability and pipeline breadth align.